Literature DB >> 31764096

Better executive function is independently associated with full HIV suppression during combination therapy.

Albert M Anderson1, Josué Pérez-Santiago, Ziduo Zheng, Eugene Huang, Donald Franklin, Jennifer Iudicello, David J Moore, Ronald J Ellis, Robert K Heaton, Scott L Letendre.   

Abstract

OBJECTIVE: HIV-associated neurocognitive impairment continues to be prevalent and clinically relevant. We examined the relationship between neurocognition and full plasma HIV RNA suppression among study participants over a 15-year period at a large research program. DESIGN/
METHODS: We analyzed the combined prospective studies of the HIV Neurobehavioral Research Program at the University of California at San Diego. Participants were eligible for analysis if on three drug combination antiretroviral therapy with comprehensive neuropsychological testing results. Participants who reported recent nonadherence were excluded. The primary outcome was plasma HIV RNA of 50 copies/ml or less. Generalized estimating equation was used to assess for associations with full virologic suppression taking into account longitudinal visits.
RESULTS: There were 1943 participants at baseline, of whom 69.4% had plasma HIV RNA of 50 copies/ml or less. Participants with full suppression were slightly older, less likely to abuse cocaine, and had significantly better executive function. Multivariate analysis with incorporation of longitudinal visits (total = 5555) confirmed current cocaine abuse to be strongly associated with lack of virologic suppression (odds ratio = 0.45, 95% confidence interval = 0.31-0.63). In contrast, increasing age, increasing years of HIV infection, and increasing executive function (odds ratio = 1.18 for T score change of 10, 95% confidence interval = 1.07-1.30) were associated with full virologic suppression. Lack of virologic suppression at baseline was associated with a significant subsequent decline in executive function.
CONCLUSION: In a 15-year research cohort of almost 2000 HIV-infected individuals on combination antiretroviral therapy, better executive function was associated with full virologic suppression, possibly as a result rather than a cause.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31764096      PMCID: PMC6905116          DOI: 10.1097/QAD.0000000000002348

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  29 in total

1.  Action (verb) fluency: test-retest reliability, normative standards, and construct validity.

Authors:  Steven Paul Woods; J Cobb Scott; Danielle A Sires; Igor Grant; Robert K Heaton; Alexander I Tröster
Journal:  J Int Neuropsychol Soc       Date:  2005-07       Impact factor: 2.892

2.  Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.

Authors:  Ned Sacktor; Richard L Skolasky; Eric Seaberg; Cynthia Munro; James T Becker; Eileen Martin; Ann Ragin; Andrew Levine; Eric Miller
Journal:  Neurology       Date:  2015-12-30       Impact factor: 9.910

3.  Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version.

Authors:  Marc A Norman; David J Moore; Michael Taylor; Donald Franklin; Lucette Cysique; Chris Ake; Deborah Lazarretto; Florin Vaida; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2011-06-24       Impact factor: 2.475

4.  Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse.

Authors:  Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

5.  The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples.

Authors:  Michael C Diehr; Mariana Cherner; Tanya J Wolfson; S Walden Miller; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2003-06       Impact factor: 2.475

6.  The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.

Authors:  Sergio Serrano-Villar; Carolina Gutiérrez; Alejandro Vallejo; Beatriz Hernández-Novoa; Laura Díaz; María Abad Fernández; Nadia Madrid; Fernando Dronda; Javier Zamora; María Ángeles Muñoz-Fernández; Santiago Moreno
Journal:  J Infect       Date:  2012-10-06       Impact factor: 6.072

7.  Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons.

Authors:  Adriana S A Andrade; Reena Deutsch; Shivaun A Celano; Nichole A Duarte; Thomas D Marcotte; Anya Umlauf; J Hampton Atkinson; J Allen McCutchan; Donald Franklin; Terry J Alexander; Justin C McArthur; Christina Marra; Igor Grant; Ann C Collier
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

8.  The effects of low literacy and cognitive impairment on medication adherence in HIV-positive injecting drug users.

Authors:  Drenna Waldrop-Valverde; Deborah L Jones; Stephen Weiss; Mahendra Kumar; Lisa Metsch
Journal:  AIDS Care       Date:  2008-11

9.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

Review 10.  Medication Adherence Measures: An Overview.

Authors:  Wai Yin Lam; Paula Fresco
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.